Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a european organization for research in cancer therapy genitourinary group trial

Journal of Urology

Volumn 162, Issue 5, 1999, Pages 1658-1665

  De Reijke, Theo M ^a   Keuppens, Frans I ^a   Whelan, Peter ^a   Kliment, Jan ^a   Robinson, Mel R G ^a   Rea, Lesley Ann ^a   Sylvester, Richard J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Drug therapy; Hormones; Neoplasm metastasis; Prognosis; Prostate neoplasms

Indexed keywords

MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; ORCHIECTOMY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032862254     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68191-8     Document Type: Article

References (28)

1. Kozlowski, J. M., Ellis, W. J. and Grayhack, J. T.: Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol. Clin. N. Amer., 18: 15, 1991.
2. de Voogt, H. J., Suciu, S., Sylvester, R., Pavone-Macaluso, M., Smith, P. H. and de Pauw, M.: Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of cancer trials. J. Urol., 141: 883, 1989.
3. Anonymous.: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet, 346: 265, 1995.
4. Isaacs, J. T. and Coffey, D. S.: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning 3327-H adenocarcinoma. Cancer Res., 41: 5070, 1981.
5. Goldenberg, S. L., Bruchovsky, N., Gleave, M. E., Sullivan, L. D. and Akakura, K.: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology, 45: 839, 1995.
6. van Poppel, H., van den Broucke, F., Derluyn, J., Popelier, G., Casselman, J., Billiet, I., van Uytsel, L., Paridaens, R. and Baert, L.: Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: Preliminary results on a randomized trial. J. Urol., 149: 1485, 1993.
7. Torti, F. M. and Carter, S. K.: The chemotherapy of prostate adenocarcinoma. Ann. Intern. Med., 92: 681, 1980.
8. Eisenberger, M. A., Bezerdjian, L. and Kalash, S.: A critical assessment of the role of chemotherapy for endocrine resistant prostatic carcinoma. AUA Update Series, vol. 7, p. 218, 1988.
9. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M. and Murphy, K. C.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol., 14: 1756, 1996.
10. Servadio, C., Mukamel, E., Lurie, H. and Nissenkorn, I.: Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology, 21: 493, 1983.
11. Janknegt, R. A., Boon, T. A., van de Beek, C. and Grob, P.: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology, 49: 411, 1997.
12. Miyake, H., Hara, I., Fujisawa, M., Eto, H., Okada, H., Arakawa, S. and Kamidono, S.: Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical Stage D prostatic cancer. Int. J. Urol., 3: 472, 1996.
13. Jones, W. G., Fosså, S. D., Bono, A. V., Croles, J. J., Stoter, G., de Pauw, M. and Sylvester, R.: Mitomycin-C in the treatment of metastatic prostate cancer: Report on an EORTC phase II study. World J. Urol., 4: 182, 1986.
14. Newling, D. W., Fossa, S. D., Tunn, U. W., Kurth, K. H., de Pauw, M. and Sylvester, R.: Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study. J. Urol., 150: 1840, 1993.
15. International Union Against Cancer: TNM Classification of Malignant Tumours, 4th ed. Edited by P. Hermanek and L. H. Sobin. New York: Springer-Verlag, 1978.
16. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO offset publication No. 48, 1979.
17. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B. and de Haes, J.: C.: The European Organisation for Research and Treatment of Cancer QLQ-C30. A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst., 85: 365, 1993.
18. Jones, B. G., Fielding, J. W., Newman, C. E., Howell, A. and Brookes, V. S.: Intravascular haemolysis and renal impairment after blood transfusion in 2 patients on long-term 5-fluorouracil and mitomycin-C. Lancet, 1: 1275, 1980.
19. Rabadi, S. J., Khandekar, J. D. and Miller, H. J.: Mitomycin-induced haemolytic uraemic syndrome: case presentation and review of literature. Cancer Treat. Rep., 66: 1244, 1982.
20. Martino, S., Baker, L. H., Pollard, R. J., Correa, J. J. and De Mattia, M. D.: Pulmonary toxicity of mitomycin. In: Mitomycin C: Current Status and New Developments. Edited by S. K. Carter, S. T. Crook and N. A. Alder. New York: Academic Press, pp. 231-242, 1979.
21. Maier, U., Höbarth, K. and Simak, R.: Primary metastatic carcinoma of the prostate in younger men: a plea to think over usual therapeutic strategies. Eur. Urol., 29: 221, 1996.
22. Roessler, W., Hinke, A. and Wieland, W. F.: Experience in advanced prostate cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate. Urology, suppl., 43: 57, 1994.
23. Osborne, C. K., Blumenstein, B., Crawford, E. D., Coltman, C. A., Jr., Smith, A. Y., Lambuth, B. W. and Chapman, R. A.: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J. Clin. Oncol., 8: 1675, 1990.
24. Kubota, Y., Nakada, T., Imai, K, Yamanaka, H., Sakai, H., Saito, Y., Tomaru, Y., Kitamura, K., Sugano, O. and Sasagawa, I.: Chemo-endocrine therapy in patients with stage D2 prostate cancer. Prostate, 26: 50, 1995.
25. Uekado, Y., Hirano, A., Inagaki, T., Hiroi A. and Watanabe, T.: Combined hormone and chemotherapy for the patients with advanced prostate cancer. Jap. J. Cancer Chemother., 22: 1041, 1995.
26. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Wilding, G. and Blumenstein, B.: Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adenocarcinoma of the prostate (CaP): results of NCI Intergroup Study 0105 (SWOG and ECOG). J. Urol., part 2, 157: 336, abstract 1311, 1997.
27. Pummer, K., Lehnert, M., Stettner, H. and Hubmer, G.: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur. Urol., suppl., 32: 81, 1997.
28. Fossa, S. D., Curran, D., Aaronson, N. K., Keuppens, F., Kliment, J., Robinson, M. R. G., De Reijke, Th. M., Hetherington, J., Kil, P. J. M. and Rea, L. A.: Quality of life in patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy with or without mitomycin C: results from EORTC phase III trial 30893. Eur. Urol., in press, 1999.